Dapoxe-tine CAS 119356-77-3

Product Description:

Product Name: Dapoxe-tine CAS NO: 119356-77-3

Synonyms:

Priligy;

Dapoxetina;

(1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine;

Chemical & Physical Properties:

Appearance: White to off-white crystalline powder

Assay :≥99.0%

Density: 1.081 g/cm3

Boiling Point: 454.4℃at 760mmHg

Flash Point: 132.6℃

Refractive Index: 1.607

Vapor Pressure: 1.91E-08mmHg at 25℃

Safety Information:

HS Code: 2922199090

Dapoxe-tine, marketed as Priligy and Westoxetin, among and other brands, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxe-tine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of selective serotonin reuptake inhibitor (SSRI) family, dapoxe-tine was initially created as an antidepressant. However, unlike other SSRIs, dapoxe-tine is absorbed and eliminated rapidly in the body. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant.

Originally created by Eli Lilly pharmaceutical company, dapoxe-tine was sold to Johnson & Johnson in 2003 and submitted as a New Drug Application to the Food and Drug Administration (FDA) for the treatment of PE in 2004. Dapoxe-tine has been sold in several European and Asian countries, and lately in Mexico. In the US, dapoxe-tine has been stuck in phase III development since 2003. However, it is expected to be marketed soon. In 2012, Menarini acquired the rights to commercialise Priligy in Europe, most of Asia, Africa, Latin America and the Middle East.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.